General
Preferred name
dalpiciclib
Synonyms
SHR-6390 ()
Dalpiciclib (hydrochloride) ()
SHR-6390 (hydrochloride) ()
P&D ID
PD133873
CAS
1637781-04-4
2891598-76-6
Tags
available
drug
Drug Status
approved
investigational
Max Phase
3.0
Drug indication
Esophageal squamous cell carcinoma
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION The chemical structure submitted to the WHO for the INN dalpiciclib is identical to that of the orally administered CDK4/6 inhibitor SHR6390, via a PubChem structure match. Pharmacological and preclinical anti-tumour data for SHR6390 have been published , albeit without name>structure disclosure. SHR6390 was designed by Jiangsu Hengrui Medicine Company. (GtoPdb)
DESCRIPTION Dalpiciclib (SHR-6390) is an orally active and highly selective inhibitor of CDK4 and 6 with IC50 values of 12.4 nM and 9.9 nM, respectively[1][2]. Dalpiciclib shows antitumor activity against breast cancer and esophageal squamous cell carcinoma[1][2][3][4].
PRICE 546
DESCRIPTION Dalpiciclib (SHR-6390) is a highly selective, orally bioavailable, and comparable potency inhibitor of CDK4 and CKD6 with IC50s of 12.4?nM and 9.9?nM, respectively. Dalpiciclib exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated tumor suppressor retinoblastoma protein (Rb) and inducing G1 cell cycle arrest.
DESCRIPTION Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC50 values of 12.4 nM and 9.9 nM, respectively[1][2]. Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal squamous cell carcinoma[1][2][3][4].
DESCRIPTION Dalpiciclib (SHR-6390) is a highly selective, orally bioavailable, and comparable potency inhibitor of CDK4 and CKD6 with IC50s of 12.4 nM and 9.9 nM, respectively. Dalpiciclib exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated tumor suppressor retinoblastoma protein (Rb) and inducing G1 cell cycle arrest. (TargetMol Bioactive Compound Library)
Compound Sets
6
ChEMBL Drugs
CHEMBL4802161
DrugBank
DB17456
Guide to Pharmacology
11189
MedChem Express Bioactive Compound Library
HY-114338
HY-114338A
PKIDB
TargetMol Bioactive Compound Library
T9636
External IDs
14
Properties
(calculated by RDKit )
Molecular Weight
446.24
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
5
Aromatic Ring Count
3
cLogP
4.02
TPSA
101.8
Fraction CSP3
0.48
Chiral centers
0.0
Largest ring
6.0
QED
0.57
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
CDK
CDK4
CDK6
Pathway
Cell Cycle/DNA Damage
Cell Cycle/Checkpoint
Source data